Big liquor brands regain market share after excise policy changes in AP
The overall market share of liquor brands owned by multinational companies (MNCs) and brands with a national presence have reached 56% — an increase of more than 150% compared to their presence during the previous YSRCP regime.
The market share of lesser-known brands has decreased to just 7%, which used to be 68% during the previous regime. None of the suppliers have more than 20% of the market share.
According to excise minister Kollu Ravindra, the reason for the increase in market share of well-established brands is the automated order-placing system. "We are placing orders as per the demand from consumers. We didn't do anything either to favour a particular brand or to prevent any brand from accessing the market in AP.
Our system places indents based on the demand and supply mechanism without any manual intervention," explained Ravindra.
While MNCs had a negligible presence during the previous regime, a few companies with national presence like Tilak Nagar Industries (8%), Radico Khaitan (6%), and Jagatjit Industries (3%) got a share in the market before the NDA govt came to power in the state in June 2024. The other top 25 brands together had only 11% of the market share.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
You Won't Believe the Price of These Dubai Apartments
Binghatti Developers FZE
Get Offer
Undo
After the change of policy by the NDA govt in the state, the market share of Tilak Nagar Industries increased to 12%, while that of Radico Khaitan rose to 18%. Pernod Ricard and United Spirits, which vanished from the state during the previous regime, have now gained 7% and 12% market share, respectively. Even the market share of other top 25 brands has increased from 11% to 18% after the NDA govt came to power.
Another significant difference, according to Ravindra, is the reduction in illicit liquor.
"There has been a remarkable improvement on this front as nine districts have been declared illicit liquor-free. Non-availability of favoured brands is one reason for people to opt for illicit liquor. Operation Navodayam launched against this menace is giving good results, and we are confident of making more districts arrack-free in the coming days," said Ravindra.
HIC HIC HOORAY
Market share of various companies before and after the new excise policy (in %)
MNC Brands
United Spirits | 0 to 11.4
Pernod Ricard | 0 to 7.3
Brands with national presence
Radico Khaitan | 6.2 to 18.3
Tilaknagar Industries | 8.2 to 11.4
Allied Blenders | 1.4 to 7.7
InBrew | 1.8 to 6.6
John Distilleries | 0 to 6.2
Other Top 25 brands
11.1 to 19.3
Lesser-known brands
68.2 to 7.2
Prices have come down by Rs 10 to Rs 100 on various brands of liquor and beer
Excise dept estimates Rs 110 crore savings per month for consumers due to price reduction
Prices of 30 brands having a market share of 87% in AP are lower than in Telangana, Karnataka, and Tamil Nadu
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
13 minutes ago
- India.com
India's Pharma Exports Have Shot Up By 92% In Last 6 Years: Minister
New Delhi: Various schemes being implemented by the Centre to realise the vision of Aatmanirbhar Bharat in the pharmaceutical sector have resulted in India's exports of drugs and pharmaceuticals increasing by 92 per cent, from Rs 1,28,028 crore in FY2018-19 to Rs 2,45,962 crore in FY2024-25, the Parliament was informed on Friday. The schemes include the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, the PLI Scheme for Bulk Drugs, Scheme for Promotion of Bulk Drug Parks, and Strengthening of Pharmaceutical Industry scheme, Minister of State for Chemicals and Fertilisers Anupriya Patel told the Lok Sabha in a written reply to a question. The PRIP scheme has been launched with an outlay of Rs 5,000 crore to transform India's Pharma MedTech sector from cost- to innovation-based growth by strengthening research and promoting industry-academia linkage for research and development in priority areas in drug discovery and development and medical devices. Under this scheme, seven Centres of Excellence (CoEs) have been set up, she said. The PLI Scheme for Pharmaceuticals aims to enhance India's manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. The minister said that the scheme has enabled enhanced investment and production in eligible products. As of March 2025, the committed investment of Rs 17,275 crore targeted over the six-year period of the scheme stands substantially exceeded with a cumulative investment of Rs 37,306 crore made by the scheme's third year, and cumulative sales of approved products of Rs 2,66,528 crore have been made, including exports of Rs 1,70,807 crore. The PLI Scheme for Bulk Drugs, which has a total budgetary outlay of Rs 6,940 crore, aims to avoid disruption in the supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on a single source. As of March 2025, the committed investment of Rs 3,938.5 crore under projects approved under the scheme for investment over the six-year production period of the scheme stands substantially exceeded with a cumulative investment of Rs 4,570 crore made by the scheme's third year, she further stated. The minister also highlighted that the government launched the Pradhan Mantri Bhartiya Janaushadhi Pariyojana scheme to make quality generic medicines available at affordable prices to all. Under the scheme, dedicated outlets known as Jan Aushadhi Kendras (JAKs) are opened across the country to provide medicines at prices that are about 50 per cent to 80 per cent lower than those of leading branded medicines in the market. Till June 6, 2025, a total of 16,912 JAKs have been opened, and on average, about 10 to 12 lakh persons visit these Kendras daily and avail of quality medicines at affordable prices. As many as 2,110 medicines and 315 surgicals, medical consumables and devices are under the scheme product basket, covering all major therapeutic groups, such as cardiovascular, anti-cancer, anti-diabetic, anti-infectives, anti-allergic and gastro-intestinal medicines and nutraceuticals. As a result of the scheme, in the last 11 years, estimated savings of about Rs 38,000 crore have accrued to citizens in comparison to the prices of branded medicines. Further, the scheme has provided self-employment to over 16,000 persons, including over 6,800 women entrepreneurs, the minister added.
News18
20 minutes ago
- News18
Hyundai India Gets Rs 517.34 Cr Tax With Penalty Demand From GST Authority, Here's Why
Last Updated: The company said there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. Hyundai Motor India Ltd on Tuesday said it has received a demand of Rs 517.34 crore from tax authorities, along with penalty, for alleged short payment of GST compensation cess on its certain SUV models. The company has received an order from Commissioner (Appeals), CGST Dept, Tamil Nadu, confirming GST compensation cess demand of Rs 258.67 crore, along with penalty of Rs 258.67 crore, on the allegation of short payment of GST compensation cess on certain SUV models for the period September 2017 – March 2020, Hyundai Motor India Ltd said in a regulatory filing. Reacting to the demand, a company spokesperson said, 'HMIL is of the view that the amendment and the clarifications given by the Central Board of Indirect Tax and Customs (CBIC) to resolve the issue faced by the industry on this matter are in favour of the company. We are in the process of reviewing the order and will exercise the right to seek a legal remedy through an appropriate forum." The company asserted that there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. . view comments First Published: July 26, 2025, 08:17 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
25 minutes ago
- Time of India
Atal Pension Yojana enrolments cross 8 crore mark; adds 39 lakh new subscribers so far in FY26
Social Security scheme Atal Pension Yojana has crossed 8 crore total gross enrolments, with an addition of 39 lakh new subscribers so far in the current fiscal, the Finance Ministry said on Friday. APY was launched on May 9, 2015. Explore courses from Top Institutes in Please select course: Select a Course Category Technology others Digital Marketing MBA Operations Management Healthcare MCA healthcare Data Analytics Management Cybersecurity Finance Leadership Others Project Management PGDM Public Policy Data Science Artificial Intelligence CXO Design Thinking Product Management Degree Data Science Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details "The Atal Pension Yojana (APY), a flagship social security scheme of the Government of India administered by PFRDA , has achieved a significant milestone by surpassing 8 crore total gross enrolments with an addition of 39 lakh new subscribers in the current Financial Year (FY 2025-26) alone," the ministry said in a statement. Launched with a vision to create a universal social security system for all Indians, APY is a voluntary, contributory pension scheme , focused on the poor, the underprivileged, and workers in the unorganised sector. APY assures a guaranteed monthly pension of Rs 1,000 to Rs 5,000 for the subscriber post-60 years of age, the same pension to the spouse after the subscriber's demise, and return of the accumulated corpus to the nominee after the death of both. It is open to all Indian citizens between the age of 18-40 years, except those who are or have been income tax payers.
